Join our daily newsletter At The Bell to receive exclusive market insights
LTR Pharma (ASX:LTP) has posted final study results showing its ‘nasal viagra’ drug SPONTAN is absorbed 470% faster than oral tablets.
The data ultimately underscores that value proposition very serious investment analysts on George St have been eyeing – a superior product that can produce erections in far faster timeframes.
While the subject matter may be joke-inducing, the value proposition is real. A lot can happen in the forty minutes it takes for better known oral solutions to work.
LTR Pharma also reported on Monday the product – and this is by way of it being sprayed directly up the nose – has a greater bioavailability than oral tablets. (In that light, it would be fair to say “of course it does.”)
Still, the mode of delivery enables the company to post better performance results than that of its oral-pill-based-competitors.
The drug was well tolerated with no adverse effects reported. The company says its drug is overall as safe as oral tablets.
“The rapid onset of action and pharmacokinetic profile of SPONTAN® have the potential to address significant unmet needs in erectile dysfunction treatment” LTP CMO Prof. Geoffrey Strange said.
“The speed of absorption, coupled with the excellent bioavailability and safety profile, offers patients a more spontaneous and convenient therapeutic option.”
LTP last traded at $1.93/sh.
Join the discussion: See what HotCopper users are saying about LTR Pharma and be part of the conversations that move the markets.
